You are here

DANA; A Tool to Detect Cognitive Changes in Pre-clinical and MCI Patients

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R44AG063635-01
Agency Tracking Number: R44AG063635
Amount: $290,793.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIA
Solicitation Number: PAR17-067
Timeline
Solicitation Year: 2017
Award Year: 2019
Award Start Date (Proposal Award Date): 2019-07-01
Award End Date (Contract End Date): 2019-12-31
Small Business Information
8737 COLESVILLE RD STE L 203
Silver Spring, MD 20910-3937
United States
DUNS: 128374548
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 CORINNA LATHAN
 (301) 495-0770
 clathan@atinc.com
Business Contact
 CHARLOTTE SAFOS
Phone: (301) 495-0770
Email: csafos@atinc.com
Research Institution
N/A
Abstract

Project Summary Abstract The goal of this proposed two phase project is to develop the Digital Automated Neurobehavioral AssessmentDANAapp into a tool that can be easily used by patients with Mild Cognitive ImpairmentMCIand Alzheimer s diseaseADand can provide clinicians with meaningful data in the tracking and diagnosis of these conditionsDANA is an FDA cleared neurocognitive assessment tool that has been previously used with similar populations and has been shown to be a valid and reliable method for screening cognitive functioning and tracking changes in cognitive functioning over timeThe specific aims of the proposal arein Phase IDetermine technical feasibility and diagnostic accuracy of high frequency cognitive testing with DANAin Phase IITechnical development of DANA for in home useandEstablish predictive validity of DANA for the early detection of Alzheimer s diseaseIn Phase Ithis project will implement a pilot studyMCI patients and normal controls will take DANA both in clinic and at home in order to examine the feasibility of this population using DANA in the home and DANA s ability to discriminate between healthy and impaired usersIn Phase IIthis project will build on the results of Phase I to technically refine the DANA tool to better fit the needs of MCI patientsThe refined app will be deployed in an experimentinvolving MCI patients and normal controlsthat will establish the predictive validity of DANA for the early detection of Alzheimer s disease Project Narrative Tracking the progression of Alzheimer s disease is central to planning and implementing care for sufferers of the diseaseand current methods fall short in providing the quality and depth of data needed to provide the best treatmentThis project will fill this critical gap through the development of a tool built from the existing Digital Automated Neurobehavioral AssessmentDANAapp that can collect data at regular intervals via technology tailored towards a cognitively impaired userThis new tool will also help health care providers discriminate between healthy and impaired patients

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government